Rocket Pharmaceuticals Inc (RCKT) concluded trading on Wednesday at a closing price of $2.83, with 4.49 million shares of worth about $12.72 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -76.46% during that period and on June 18, 2025 the price saw a gain of about 4.04%. Currently the company’s common shares owned by public are about 106.75M shares, out of which, 99.77M shares are available for trading.
Stock saw a price change of -6.60% in past 5 days and over the past one month there was a price change of -56.12%. Year-to-date (YTD), RCKT shares are showing a performance of -77.49% which decreased to -87.05% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.19 but also hit the highest price of $26.98 during that period. The average intraday trading volume for Rocket Pharmaceuticals Inc shares is 4.84 million. The stock is currently trading -16.13% below its 20-day simple moving average (SMA20), while that difference is down -47.16% for SMA50 and it goes to -74.90% lower than SMA200.
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) currently have 106.75M outstanding shares and institutions hold larger chunk of about 87.14% of that.
The stock has a current market capitalization of $304.90M and its 3Y-monthly beta is at 0.68. It has posted earnings per share of -$2.63 in the same period. It has Quick Ratio of 9.19 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RCKT, volatility over the week remained 4.34% while standing at 22.85% over the month.
Stock’s fiscal year EPS is expected to rise by 18.96% while it is estimated to increase by 21.86% in next year. EPS is likely to grow at an annualized rate of 20.20% for next 5-years, compared to annual growth of -11.60% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on May 30, 2025 offering an In-line rating for the stock and assigned a target price of $5 to it. Coverage by Morgan Stanley stated Rocket Pharmaceuticals Inc (RCKT) stock as an Equal-weight in their note to investors on May 28, 2025, suggesting a price target of $7 for the stock. Stock get a Hold rating from Jefferies on May 28, 2025.
